Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study

Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study

As no unified treatment protocol or evidence yet exists for plasmapheresis without plasma, this study explored the outcomes of using 4% human albumin (ALB) solution as a replacement solution in patients undergoing plasma exchange for multiple myeloma (MM) patients with acute kidney injury (AKI). Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Tianzhi Wu, Dandan Liu, Shangqin Liu, Hui Xiao, Bei Xiong, Yi Zhou, Yafen Xiong, Qin Cui, Jiang Wu, Minghui Liu, Hongli Liu, Yiming Li, Meixin Wang, Xueqin Bao, Ye Li, Fuling Zhou
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Renal Failure
Subjects:
Multiple myeloma
acute kidney injury
chemotherapy
plasmapheresis
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2024.2356708
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items